Literature DB >> 14713779

Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk.

Kala Visvanathan1, Kathy J Helzlsouer, David W Boorman, Paul T Strickland, Sandy C Hoffman, George W Comstock, Thomas G O'Brien, Yongjun Guo.   

Abstract

PURPOSE: A single nucleotide substitution of guanine to adenine (A) at base +316 in the ornithine decarboxylase (ODC) gene may be associated with greater ODC expression and increased tumor growth. ODC is induced by androgens in human prostatic epithelial cells, presumably via transcriptional activation of androgen receptor (AR) and also by nicotine. A nested case-control study was done to examine the association between this ODC genotype and prostate cancer risk, and whether it varies by AR gene CAG repeat length and smoking.
MATERIALS AND METHODS: A total of 164 cases were matched to 2 controls each from a community based cohort. ODC and AR genotyping was performed using a TaqMan (PE Applied Biosystems, Foster City, California) based assay and automated fragment analysis, respectively. Conditional logistic regression was used to estimate the OR and 95% CI.
RESULTS: The presence of the ODC A allele was not significantly associated with an increased risk of prostate cancer (OR 1.33, 95% CI 0.90 to 1.96). However, men who inherited at least 1 ODC A alleles and less than 22 AR CAG repeats were at twice the risk of prostate cancer compared with those with 2 guanine alleles and 22 or greater AR CAG repeats (OR 2.09, 95% CI 1.23 to 3.57). Smoking was associated with prostate cancer only in men carrying a least 1 ODC A allele (p interaction = 0.02).
CONCLUSIONS: The ODC A allele was not associated with a statistically significant increased risk of prostate cancer. However, this association may vary according to the number of CAG repeats in the AR receptor and smoking status.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14713779     DOI: 10.1097/01.ju.0000108384.74718.73

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis.

Authors:  Mingliang Gu; Xiaoqun Dong; Xuezhi Zhang; Wenquan Niu
Journal:  Mol Biol Rep       Date:  2011-06-12       Impact factor: 2.316

Review 2.  Targeting polyamines and inflammation for cancer prevention.

Authors:  Naveen Babbar; Eugene W Gerner
Journal:  Recent Results Cancer Res       Date:  2011

Review 3.  Polyamines and nonmelanoma skin cancer.

Authors:  Susan K Gilmour
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-29       Impact factor: 4.219

4.  Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.

Authors:  Jason A Zell; Argyrios Ziogas; Natalia Ignatenko; Jane Honda; Ning Qu; Alexander S Bobbs; Susan L Neuhausen; Eugene W Gerner; Hoda Anton-Culver
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

5.  Genetic polymorphism in ornithine decarboxylase and risk of breast cancer.

Authors:  Iain Brown; Susan Halliday; Heather Greig; Steven D Heys; Heather M Wallace; Andrew C Schofield
Journal:  Fam Cancer       Date:  2009-02-19       Impact factor: 2.375

Review 6.  A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies.

Authors:  Farhad Islami; Daniel M Moreira; Paolo Boffetta; Stephen J Freedland
Journal:  Eur Urol       Date:  2014-09-18       Impact factor: 20.096

7.  The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

Authors:  Anne R Simoneau; Eugene W Gerner; Ray Nagle; Argyrios Ziogas; Sharon Fujikawa-Brooks; Hagit Yerushalmi; Thomas E Ahlering; Ronald Lieberman; Christine E McLaren; Hoda Anton-Culver; Frank L Meyskens
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

8.  A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.

Authors:  Giselle L Saulnier Sholler; Eugene W Gerner; Genevieve Bergendahl; Robert B MacArthur; Alyssa VanderWerff; Takamaru Ashikaga; Jeffrey P Bond; William Ferguson; William Roberts; Randal K Wada; Don Eslin; Jacqueline M Kraveka; Joel Kaplan; Deanna Mitchell; Nehal S Parikh; Kathleen Neville; Leonard Sender; Timothy Higgins; Masao Kawakita; Kyoko Hiramatsu; Shun-Suke Moriya; André S Bachmann
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

9.  Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.

Authors:  Hong Weng; Sheng Li; Jing-Yu Huang; Zi-Qi He; Xiang-Yu Meng; Yue Cao; Cheng Fang; Xian-Tao Zeng
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

10.  Androgen receptor CAG and GGN repeat length variation contributes more to the tumorigenesis of osteosarcoma.

Authors:  Yongxiang Shi; Weishan Chen; Qinghuai Li; Zhaoming Ye
Journal:  Oncotarget       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.